GlassScriptPhysician profile
Lauren Herrera
NPI 1689397424
$3,414.05
in general payments reported to CMS, 2019-2025
28 companies · $1,204 in 2025
The $1,204 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $341 · 2023: $863 · 2024: $1,006 · 2025: $1,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,072.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $821.13 | 2022-2025 | Sogroya, Norditropin, Wegovy |
| Sanofi-Aventis U.S. LLC | $340.00 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $316.64 | 2023-2025 | Triptodur, Triptodur |
| Abbvie INC. | $314.20 | 2022-2025 | |
| Ascendis Pharma Endocrinology INC | $291.06 | 2022-2025 | Skytrofa |
| Tolmar, INC. | $195.61 | 2023-2025 | Fensolvi |
| Pfizer INC. | $107.42 | 2023-2025 | |
| Dexcom, INC. | $98.92 | 2023-2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $87.94 | 2023-2024 | Crysvita |
| Zealand Pharma US, INC. | $87.82 | 2022 | |
| Eton Pharmaceuticals, INC. | $76.00 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Genzyme Corporation | $72.63 | 2025 | |
| Neurocrine Biosciences, INC. | $69.19 | 2024-2025 | |
| Endo USA, INC. | $61.95 | 2024-2025 | Supprelin |
| Alexion Pharmaceuticals, INC. | $54.45 | 2024-2025 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $54.04 | 2025 | Vykat Xr |
| Sequel Med Tech, LLC | $50.42 | 2025 | Twiist |
| Amphastar Pharmaceuticals, INC. | $47.92 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $42.56 | 2023-2025 | Gvoke Hypopen |
| Insulet Corporation | $40.80 | 2022-2023 | Omnipod |
| Sandoz INC. | $32.40 | 2025 | Omnitrope |
| Medline Industries LP | $31.33 | 2024 | |
| Embecta Corp. | $23.40 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Arbor Pharmaceuticals, INC. | $22.51 | 2022 | |
| Smith+Nephew, INC. | $19.54 | 2023 | Collagenase Santyl |
| Abbott Laboratories | $19.17 | 2025 | Freestyle Libre 3 |
| Tolmar Pharmaceuticals, INC. | $18.07 | 2022 | |
| Beta Bionics, INC. | $16.93 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Herrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.